Association of Cystatin C with Adverse Outcomes

Overview

Journal Curr Opin Nephrol Hypertens

Specialties Cardiology & Vascular Diseases
Nephrology

Date 2009 Apr 18

PMID 19374014

Citations 20

Authors

Magdalena Madero

Mark J Sarnak

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: To discuss recent studies which have evaluated determinants of cystatin C and to focus on the relationship of cystatin C with mortality, cardiovascular disease (CVD), and noncardiovascular outcomes.

Recent Findings: In the Chronic Kidney Disease Epidemiology Study cystatin C was associated with demographic characteristics independent of measured glomerular filtration rate (GFR), although this was to a smaller extent than creatinine. In patients with established chronic kidney disease (CKD), cystatin C was strongly and inversely correlated with measured GFR, suggesting that although cystatin C may have other determinants, it is primarily a measure of kidney function. Several cohort studies, particularly in older adults, have now demonstrated that cystatin C is linearly associated with mortality, CVD and non-CVD outcomes, whereas creatinine is primarily associated with risk in individuals with more advanced kidney disease. A recent study has also shown that changes in kidney function as ascertained by cystatin C, even within the relatively normal range, are associated with subsequent CVD and all-cause mortality among older adults.

Summary: Cystatin C appears to capture an association of mild kidney disease with increased risk of mortality, CVD and non-CVD outcomes. Future studies should evaluate whether cystatin C can improve medical decision-making and lead to favorable patient outcomes.

Citing Articles

Insights into Cognitive Brain Health in Chronic Kidney Disease.

Tariq H, Ramakrishnan M, Gupta A Gerontol Geriatr. 2023; 8(2).

PMID: 37671071 PMC: 10478617. DOI: 10.26420/gerontolgeriatrres.2022.1074.

Should Cystatin C eGFR Become Routine Clinical Practice?.

Spencer S, Desborough R, Bhandari S Biomolecules. 2023; 13(7).

PMID: 37509111 PMC: 10377068. DOI: 10.3390/biom13071075.

Trends in Passive IoT Biomarker Monitoring and Machine Learning for Cardiovascular Disease Management in the U.S. Elderly Population.

Bender B, Berry J Adv Geriatr Med Res. 2023; 5(1).

PMID: 37274061 PMC: 10237513. DOI: 10.20900/agmr20230002.

Non-linear association of cystatin C and all-cause mortality of heart failure: A secondary analysis based on a published database.

Zheng T, Tang A, Huang Y, Chen J Front Cardiovasc Med. 2022; 9:930498.

PMID: 36148067 PMC: 9488665. DOI: 10.3389/fcvm.2022.930498.

A Review of Specific Biomarkers of Chronic Renal Injury and Their Potential Application in Nonclinical Safety Assessment Studies.

Obert L, Elmore S, Ennulat D, Frazier K Toxicol Pathol. 2021; 49(5):996-1023.

PMID: 33576319 PMC: 8195817. DOI: 10.1177/0192623320985045.

References

Shlipak M, Katz R, Fried L, Jenny N, Stehman-Breen C, Newman A . Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol. 2005; 45(2):268-71. DOI: 10.1016/j.jacc.2004.09.061. View

Djousse L, Kurth T, Gaziano J . Cystatin C and risk of heart failure in the Physicians' Health Study (PHS). Am Heart J. 2007; 155(1):82-6. PMC: 2179893. DOI: 10.1016/j.ahj.2007.08.023. View

McManus D, Shlipak M, Ix J, Ali S, Whooley M . Association of cystatin C with poor exercise capacity and heart rate recovery: data from the heart and soul study. Am J Kidney Dis. 2007; 49(3):365-72. PMC: 2770341. DOI: 10.1053/j.ajkd.2006.12.016. View

Risch L, Herklotz R, Blumberg A, Huber A . Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. Clin Chem. 2001; 47(11):2055-9. View

Sarnak M, Katz R, Fried L, Siscovick D, Kestenbaum B, Seliger S . Cystatin C and aging success. Arch Intern Med. 2008; 168(2):147-53. PMC: 2871318. DOI: 10.1001/archinternmed.2007.40. View

Small G, Rabins P, BARRY P, Buckholtz N, DeKosky S, Ferris S . Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA. 1997; 278(16):1363-71. View

Rifkin D, Shlipak M, Katz R, Fried L, Siscovick D, Chonchol M . Rapid kidney function decline and mortality risk in older adults. Arch Intern Med. 2008; 168(20):2212-8. PMC: 2879064. DOI: 10.1001/archinte.168.20.2212. View

Fried L, Katz R, Sarnak M, Shlipak M, Chaves P, Jenny N . Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol. 2005; 16(12):3728-35. DOI: 10.1681/ASN.2005040384. View

Retnakaran R, Connelly P, Harris S, Zinman B, Hanley A . Cystatin C is associated with cardiovascular risk factors and metabolic syndrome in Aboriginal youth. Pediatr Nephrol. 2007; 22(7):1007-13. DOI: 10.1007/s00467-007-0471-9. View

10.

Arpegard J, Ostergren J, de Faire U, Hansson L, Svensson P . Cystatin C--a marker of peripheral atherosclerotic disease?. Atherosclerosis. 2008; 199(2):397-401. DOI: 10.1016/j.atherosclerosis.2007.11.025. View

11.

Koenig W, Twardella D, Brenner H, Rothenbacher D . Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem. 2004; 51(2):321-7. DOI: 10.1373/clinchem.2004.041889. View

12.

Kottgen A, Selvin E, Stevens L, Levey A, Van Lente F, Coresh J . Serum cystatin C in the United States: the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2008; 51(3):385-94. DOI: 10.1053/j.ajkd.2007.11.019. View

13.

Fried L, Shlipak M, Stehman-Breen C, Mittalhenkle A, Seliger S, Sarnak M . Kidney function predicts the rate of bone loss in older individuals: the Cardiovascular Health Study. J Gerontol A Biol Sci Med Sci. 2006; 61(7):743-8. DOI: 10.1093/gerona/61.7.743. View

14.

Jernberg T, Lindahl B, James S, Larsson A, Hansson L, Wallentin L . Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation. 2004; 110(16):2342-8. DOI: 10.1161/01.CIR.0000145166.44942.E0. View

15.

Knight E, Verhave J, Spiegelman D, Hillege H, de Zeeuw D, Curhan G . Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004; 65(4):1416-21. DOI: 10.1111/j.1523-1755.2004.00517.x. View

16.

Manetti L, Pardini E, Genovesi M, Campomori A, Grasso L, Morselli L . Thyroid function differently affects serum cystatin C and creatinine concentrations. J Endocrinol Invest. 2005; 28(4):346-9. DOI: 10.1007/BF03347201. View

17.

Muntner P, Winston J, Uribarri J, Mann D, Fox C . Overweight, obesity, and elevated serum cystatin C levels in adults in the United States. Am J Med. 2008; 121(4):341-8. PMC: 3049932. DOI: 10.1016/j.amjmed.2008.01.003. View

18.

Odden M, Chertow G, Fried L, Newman A, Connelly S, Angleman S . Cystatin C and measures of physical function in elderly adults: the Health, Aging, and Body Composition (HABC) Study. Am J Epidemiol. 2006; 164(12):1180-9. DOI: 10.1093/aje/kwj333. View

19.

Donahue R, Stranges S, Rejman K, Rafalson L, Dmochowski J, Trevisan M . Elevated cystatin C concentration and progression to pre-diabetes: the Western New York study. Diabetes Care. 2007; 30(7):1724-9. DOI: 10.2337/dc07-0040. View

20.

Yaffe K, Lindquist K, Shlipak M, Simonsick E, Fried L, Rosano C . Cystatin C as a marker of cognitive function in elders: findings from the health ABC study. Ann Neurol. 2008; 63(6):798-802. PMC: 2584446. DOI: 10.1002/ana.21383. View